Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

8.925 -0.465 (-4.95%)
Streaming Delayed Price Updated: 9:53 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
3 Volatile Stocks Walking a Fine Line
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
Analyst Expectations For 10x Genomics's Future
Via Benzinga
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Stocks Under $10 Walking a Fine Line
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
Earnings Scheduled For May 8, 2025
Via Benzinga
Earnings Scheduled For February 12, 2025
Via Benzinga
The Analyst Verdict: 10x Genomics In The Eyes Of 6 Experts
Via Benzinga
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
Via Benzinga
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance
10x Genomics Inc. criticized U.S. government budget cuts for academic research, withdrew full-year guidance, and shifted to quarterly forecasts. 
Via Benzinga
10x Genomics’s (NASDAQ:TXG) Q1: Strong Sales But Quarterly Revenue Guidance Significantly Misses Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s... 
Via StockStory
10x Genomics (TXG) Reports Q1: Everything You Need To Know Ahead Of Earnings
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Pours $9.8 Million In Robinhood Despite Crypto Revenue Slump, Keeps Dumping Palantir Ahead Of Earnings
Cathie Wood's Ark Invest Makes Bold $9.8M Robinhood Bet While Dumping Palantir Ahead of Earnings. 
Via Benzinga
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs. 
Via Benzinga
3 Cash-Heavy Stocks in the Doghouse
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs
On Wednesday, April 23, 2025, Cathie Wood of Ark Invest purchased more stock of AMD and Nvidia amid looming US chip curbs against China. 
Via Benzinga
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most... 
Via StockStory
Topics Artificial Intelligence Government World Trade
Exposures Artificial Intelligence Political Tariff
Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Reasons to Sell TXG and 1 Stock to Buy Instead
What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many shareholders. This was partly due to its softer quarterly results and might have... 
Via StockStory
1 Stock Under $50 on Our Watchlist and 2 to Ignore
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns. 
Via Benzinga
Why 10x Genomics (TXG) Shares Are Falling Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full-year... 
Via StockStory
MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s... 
Via StockStory
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 
Via StockStory
Cathie Wood's Ark Invest Bets Big On Amazon, Roblox And Illumina While Trimming Palantir Stake After Alex Karp-Led Company Touched An All-Time High On Thursday
Ark Invest made significant trades on Friday, including buying Amazon and Roblox stock and selling Palantir stock. Other key trades were also made. 
Via Benzinga
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox
Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV. 
Via Benzinga
Cathie Wood's Ark Invest Dumps Over $10 Million Worth Of Palantir Stock As AI Competition Heats Up
On Thursday, Jan. 30, 2025 Cathie Wood-led Ark Invest sold $10.4 million worth of Palantir shares through its flagship fund. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The aggressive growth fund investor has slowed her shopper this holiday season, but she still made time to build up some of her existing positions. 
Via The Motley Fool
Ray Dalio's Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?
Ray Dalio's Bridgewaterand Ark Invest trimmed their Microsoft positions, signaling a shift in Big Tech's role in portfolios. 
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.